News

Écoutez une entrevue récente avec Yves De Koninck qui explique comment ses recherches récentes ont permis de trouver une cible thérapeutique qui permettrait de diminuer les symptômes du sevrage aux opioïdes, comme la morphine et le fentanyl.  Cette découverte, qui a aussi permis d'identifier des médicaments déjà approuvés pour l'utilisation chez l'humain, pourrait permettre d'accélérer l'approbation de médicaments pour traiter les symptômes du sevrage de plusieurs années.

Écoutez l'entrevue sur iheartradio.ca:

The director of the Neurophotonics Centre, Yves De Koninck, will receive the Canadian Pain Society's 2017 Distinguished Career Award. This award recognizes Dr. De Koninck's longstanding contributions to pain research.
The award will be given at the next Canadian Pain Society meeting, in May 2017 in Halifax.

http://www.canadianpainsociety.ca/?page=AwardsGrant

Sentinel North, a research initiative led by Yves De Koninck and Marcel Babin from Université Laval, and funded through the Canada First Research Excellence Fund, aims to better understand the Canadian North through the use of advanced optics technologies.  Its goal is to improve our understanding of humanity, its environment and the impact environmental changes are having on humans and their health in the North. Sentinel North was recently awarded $98 million over seven years, the largest subsidy in the history of Université Laval.

Yves De Koninck was recently appointed to the Royal Society of Canada for "seminal contributions to understanding how neurons communicate at the cellular and molecular levels, in normal and pathological pain. Equally ground-breaking are his contributions to developing novel photonics technologies to push the frontiers of neuroscience".

View the Royal Society of Canada - Class of 2015 full listing.

Congratulations!